Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company.
$9.81+4.47%
报价 2026-11-06
市值
$344M
EV
$361.9M
PE (TTM)
–
预期 PE (FY2026)
34.5x
52 周区间距高点 -23.2%
$5.77$12.78
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| FENCFennec Pharmaceuticals Inc. | $344M | +4.5% | +47.4% | 92.2% | – | – | – | |
| EPRXEupraxia Pharmaceuticals Inc. | $455.2M | +4.4% | – | 0% | – | – | – | |
| AVTXAvalo Therapeutics, Inc. | $371.7M | +4.5% | 0.0% | -17,996.6% | – | – | – | |
| OBIOOrchestra BioMed Holdings, Inc. | $341.4M | +1.1% | -54.3% | 99.3% | – | – | – | |
| ENTAEnanta Pharmaceuticals, Inc. | $320.4M | +9.1% | -4.7% | 100% | – | – | – | |
| NAUTNautilus Biotechnology, Inc. | $284M | +3.7% | -61.1% | -362.5% | – | – | – | |
| RNACCartesian Therapeutics, Inc. | $227.8M | +11.1% | -70.0% | 100% | – | – | – | |
| PRLDPrelude Therapeutics Incorporated | $208.4M | +1.3% | +56.0% | 98.3% | – | – | – | |
| BDTXBlack Diamond Therapeutics, Inc. | $99.4M | +4.5% | -89.9% | 0% | – | – | – | |
| 同行中位数 | – | – | -54.3% | 49.1% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。